Sugi Predict

Sugi Predict / Compounds / SCHEMBL6174249

SCHEMBL6174249

SCHEMBL6174249

Sc1nc(-c2ccc(Br)cc2)cs1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 10/20 0.61
▸ MAPT P10636 9/20 0.61
▸ SMN1; SMN2 Q16637 8/20 0.61
▸ NPC1 O15118 7/20 0.61
▸ MEN1 O00255 7/20 0.59
▸ KMT2A Q03164 7/20 0.59
▸ ALDH1A1 P00352 4/20 0.59
▸ NPSR1 Q6W5P4 1/20 0.59
▸ LMNA P02545 5/20 0.56
▸ KDM4E B2RXH2 2/20 0.56
▸ LTA4H P09960 1/20 0.54
▸ GAA P10253 2/20 0.50
▸ MAPK1 P28482 1/20 0.47
▸ CYP19A1 P11511 1/20 0.45
▸ ALOX12 P18054 1/20 0.44
▸ POLB P06746 1/20 0.44
▸ SREBF2 Q12772 1/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3174725 0.81 RAB9A (0.68) RAB9AMAPTSMN1; SMN2NPC1MEN1
SCHEMBL9361283 0.80 LTA4H (0.63) RAB9AMAPTSMN1; SMN2NPC1MEN1
SCHEMBL3185335 0.80 RAB9A (0.56) RAB9AMAPTSMN1; SMN2NPC1MEN1
SCHEMBL178051 0.79 ALDH1A1 (0.61) RAB9AMAPTSMN1; SMN2NPC1MEN1
SCHEMBL1810828 0.79 KDM4E (0.53) RAB9AMAPTSMN1; SMN2NPC1MEN1
SCHEMBL428793 0.78 RAB9A (0.96) RAB9AMAPTSMN1; SMN2NPC1MEN1
Bromide SCHEMBL3837111 0.78 KDM4E (0.52) RAB9AMAPTSMN1; SMN2NPC1MEN1
SCHEMBL3833508 0.78 KDM4E (0.52) RAB9AMAPTSMN1; SMN2NPC1MEN1
SCHEMBL1764592 0.76 RAB9A (0.61) RAB9AMAPTSMN1; SMN2NPC1MEN1
SCHEMBL20504926 0.76 RAB9A (0.61) RAB9AMAPTSMN1; SMN2NPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105916506-B Quinazoline derivatives as inhibitors of TAM family kinases 圣诺康生命科学公司 2020-01-07 — — CN disclosed
EP-3071204-B1 QUINAZOLINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS SIGNALCHEM LIFESCIENCES CORP (CA) 2019-02-20 — — EP disclosed
US-9771333-B2 Quinazoline derivatives as TAM family kinase inhibitors SIGNALCHEM LIFESCIENCES CORP. (CA) 2017-09-26 — — US disclosed
US-20160297775-A1 QUINAZOLINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS SIGNALCHEM LIFESCIENCES CORP (CA) 2016-10-13 — — US disclosed
EP-3071204-A1 QUINAZOLINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS SignalChem Lifesciences Corp. (CA) 2016-09-28 — — EP disclosed
WO-2015077375-A1 QUINAZOLINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS SIGNALCHEM LIFESCIENCES CORP. (CA) 2015-05-28 — — WO disclosed
US-8753895-B2 Surface modified metal nano-particle and use thereof Postech Academy-Industries Foundation (KR) 2014-06-17 — — US disclosed
US-20130252274-A1 Surface Modified Metal Nano-Particle and Use Thereof POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) 2013-09-26 — — US disclosed
US-20120168681-A1 Surface Modified Metal Nano-Particle and Use Thereof POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) 2012-07-05 — — US disclosed
EP-1205472-B1 Process for the preparation of dithiazolyldisulfides BAYER AG (DE) 2005-01-26 — — EP disclosed
US-6610857-B2 Oxidation of 2-mercaptothiazoles with peroxidic compounds in an aqueous suspension BAYER AKTIENGESELLSCHAFT (DE) 2003-08-26 — — US disclosed
EP-1205472-A1 Process for the preparation of dithiazolyldisulfides BAYER AG (DE) 2002-05-15 — — EP disclosed
US-20020055640-A1 Process for the production of dithiazolyl disulfides LANXESS DEUTSCHLAND GMBH (DE) 2002-05-09 — — US disclosed
US-6248896-B1 APPROPRIATELY SUBSTITUTED 2-MERCAPTOTHIAZOLE IS OXIDIZED WITH OXYGEN OR AN OXYGEN-CONTAINING GAS IN THE PRESENCE OF A SOLVENT AND A TERTIARY AMINE AND IRON HEMIPORPHYRAZINE. BAYER AKTIENGESELLSCHAFT (DE) 2001-06-19 — — US disclosed
US-6124467-A Process for the preparation of dithiazolyl disulfides BAYER AKTIENGESELLSCHAFT (DE) 2000-09-26 — — US disclosed
EP-1008591-A1 Process for the preparation of dithiazolyldisulfides Bayer Aktiengesellschaft (DE) 2000-06-14 — — EP disclosed
US-5124450-A Reacting solution of 2-mercaptothiazole, saturated secondary heterocyclic amine, sulfur in presence of oxygen, ammonia, copper or cerium catalyst AKZO N.V. (NL) 1992-06-23 — — US disclosed
EP-0481366-A1 Process for the preparation of 2-Aminodithiothiazoles and 2-Aminotrithiothiazoles Akzo Nobel N.V. (NL) 1992-04-22 — — EP disclosed
US-4558135-A AMMONIA CATALYST AKZONA INCORPORATED (US) 1985-12-10 — — US disclosed
US-4307236-A BY CATALYTIC OXIDATION OF 2-MERCAPTO THIAZOLES AKZONA INCORPORATED (US) 1981-12-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297775-A1 QUINAZOLINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS MAP3K5, MAP3K1, MAP3K2 RAB9A 718/4885MAPT 3862/4885SMN1; SMN2 3960/4885
US-20020055640-A1 Process for the production of dithiazolyl disulfides GPX4, PRDX3, PRDX2 RAB9A 4533/4885MAPT 2206/4885SMN1; SMN2 3043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.